SOC+ BSB-2002

WITHDRAWN · PHASE1 · AML - Acute Myeloid Leukemia, AML With Mutated NPM1, AML, Adult Recurrent

Company Decision

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.